ELOX
Eloxx Pharmaceuticals, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Neutral
-14/100
Last price
15.13
▼ 0.28 (1.82%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
15.41
Day high
16.02
Day low
14.50
Volume
61.28K
Market cap
$61.07M
P/E (TTM)
4.30
52W range
8.20 – 23.40
Trailing performance
Returnvs SPY
1W
-1.88%
-3.8%
1M
+0.87%
-0.3%
3M
+23.51%
+19.0%
6M
—
-18.2%
YTD
+37.42%
+23.2%
1Y
—
-16.4%
3Y
—
-82.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on ELOX open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
769.55K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Feb 27, 26 | AGGARWAL SUMIT Chief Executive Officer |
CONVERSION | 472.83K | $39.16K | Direct |
| Jan 23, 26 | RUBIN STEVEN DANIEL Director |
— | 1.88K | — | Direct |
| Jan 23, 26 | WALTS ALAN EDMUND PH.D. Director |
— | 1.88K | — | Direct |
| Sep 19, 25 | AGGARWAL SUMIT Chief Executive Officer |
— | 1.00M | — | Direct |
| Jan 24, 25 | RUBIN STEVEN DANIEL Director |
— | 3.75K | — | Direct |
| Jan 24, 25 | AGGARWAL SUMIT Director |
— | 30.00K | — | Direct |
| Jan 24, 25 | WALTS ALAN EDMUND PH.D. Director |
— | 3.75K | — | Direct |
| Jan 24, 25 | ANDROSKI LINDSAY J.D. Director |
— | 3.75K | — | Direct |
| Oct 16, 24 | RUBIN STEVEN DANIEL Director |
— | 12.00K | — | Direct |
| Oct 16, 24 | AGGARWAL SUMIT Chief Executive Officer |
— | 165.00K | — | Direct |
| Oct 16, 24 | WALTS ALAN EDMUND PH.D. Director |
— | 12.00K | — | Direct |
| Oct 16, 24 | ANDROSKI LINDSAY J.D. Director |
— | 12.00K | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
AGGARWAL SUMIT |
Chief Executive Officer | 1.67M | Conversion of Exercise of derivative security |
ANDROSKI LINDSAY J.D. |
Director | 15.75K | Conversion of Exercise of derivative security |
RUBIN STEVEN DANIEL |
Director | 14.63K | Conversion of Exercise of derivative security |
WALTS ALAN EDMUND PH.D. |
Director | 15.57K | Conversion of Exercise of derivative security |
Fundamentals
Market cap$61.07M
Enterprise value$10.94M
Revenue (TTM)—
Gross profit—
EBITDA—
Net income$-10.65M
EPS (TTM)$3.52
Free cash flow—
Total cash$61.96M
Total debt$11.83M
Book value / share$11.50
Shares outstanding4.04M
Float931.13K
Short % of float1.25%
Dividend yield0.00%
Beta (5Y)-171,332.88
Valuation & profitability ratios
Trailing P/E4.30
Forward P/E-21.31
PEG ratio1.85
Price / sales—
Price / book1.32
EV / revenue—
EV / EBITDA—
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity—
Return on assets—
Debt / equity25.49
Current ratio3.74
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $6.36M | $0 | $0 | -100.0% |
| Operating revenue | $0 | $6.36M | $0 | $0 | -100.0% |
| Research & development | $3.06M | $3.58M | $8.60M | $23.73M | -14.6% |
| Selling, general & admin | $3.38M | $5.25M | $8.69M | $10.69M | -35.6% |
| Total operating expense | $6.44M | $8.83M | $17.29M | $34.42M | -27.1% |
| Operating income | -$6.44M | -$2.47M | -$17.29M | -$34.42M | -160.9% |
| Net interest income | -$862.00K | -$1.12M | -$899.00K | -$1.68M | +22.8% |
| Pre-tax income | -$6.00M | -$3.14M | -$17.05M | -$36.06M | -90.7% |
| Net income | -$6.00M | -$3.14M | -$17.05M | -$36.06M | -90.7% |
| Net income to common | -$6.00M | -$3.14M | -$17.05M | -$36.06M | -90.7% |
| Basic EPS | -5.39 | -9.24 | -72.93 | -183.15 | +41.7% |
| Diluted EPS | -5.39 | -9.24 | -72.93 | -183.15 | +41.7% |
| EBIT | -$4.95M | -$2.00M | -$15.90M | -$34.12M | -147.4% |
| EBITDA | -$4.95M | -$1.83M | -$15.09M | -$33.42M | -169.5% |
| Basic shares | 1.12M | 341.71K | 233.69K | 196.94K | +228.5% |
| Diluted shares | 1.12M | 341.71K | 233.69K | 196.94K | +228.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $4.79M | $111.00K | $1.13M | $19.21M | — | +4,210.8% |
| Cash & short-term investments | $4.79M | $111.00K | $1.13M | $19.21M | — | +4,210.8% |
| Accounts receivable | $0 | $2.36M | $0 | — | — | -100.0% |
| Total current assets | $5.27M | $2.98M | $1.55M | $20.13M | — | +77.1% |
| Property, plant & equipment | $0 | $0 | $164.00K | $994.00K | — | — |
| Total assets | $5.27M | $2.98M | $1.71M | $21.12M | — | +77.1% |
| Total current liabilities | $17.18M | $27.31M | $22.70M | $23.09M | — | -37.1% |
| Current debt | $1.00M | $6.52M | $2.22M | $3.98M | — | -84.7% |
| Long-term debt | — | — | $1.61M | $8.56M | $12.00M | — |
| Total debt | $1.00M | $6.52M | $3.97M | $13.38M | — | -84.7% |
| Total liabilities | $17.18M | $27.31M | $24.31M | $31.78M | — | -37.1% |
| Retained earnings | -$300.58M | -$294.58M | -$291.44M | -$274.39M | — | -2.0% |
| Shareholder equity | -$11.91M | -$24.34M | -$22.60M | -$10.66M | — | +51.1% |
| Working capital | -$11.91M | -$24.34M | -$21.15M | -$2.96M | — | +51.1% |
| Net tangible assets | -$11.91M | -$24.34M | -$22.60M | -$10.66M | — | +51.1% |
| Shares issued | 435.48K | — | 278.94K | 196.94K | 197.89K | — |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$6.00M | -$3.14M | -$17.05M | -$36.06M | — | -90.7% |
| Depreciation & amortisation | $0 | $164.00K | $809.00K | $695.00K | — | -100.0% |
| Stock-based compensation | $235.00K | $541.00K | $1.97M | $3.02M | — | -56.6% |
| Change in working capital | $520.00K | -$2.36M | $844.00K | -$118.00K | — | +122.1% |
| Operating cash flow | -$6.33M | -$4.71M | -$14.34M | -$31.84M | — | -34.2% |
| Capital expenditure | — | — | — | -$66.00K | -$89.00K | — |
| Investing cash flow | $1.00K | $38.00K | $309.00K | -$66.00K | — | -97.4% |
| Financing cash flow | $11.00M | $3.44M | -$4.08M | $8.81M | — | +219.9% |
| Free cash flow | -$6.33M | -$4.71M | -$14.34M | -$31.91M | — | -34.2% |
| End cash position | $4.79M | $116.00K | $1.35M | $19.47M | — | +4,030.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $2.84M | $1.66M | $898.00K | $510.00K | +71.2% |
| Selling, general & admin | $1.61M | $2.14M | $684.00K | $712.00K | -24.6% |
| Total operating expense | $4.45M | $3.79M | $1.58M | $1.22M | +17.3% |
| Operating income | -$4.45M | -$3.79M | -$1.58M | -$1.22M | -17.3% |
| Net interest income | $33.00K | -$6.00K | -$305.00K | -$478.00K | +650.0% |
| Pre-tax income | -$4.50M | -$3.75M | -$1.89M | -$1.71M | -19.9% |
| Net income | -$4.50M | -$3.75M | -$1.89M | -$1.71M | -19.9% |
| Net income to common | -$4.50M | -$3.75M | -$1.89M | -$1.71M | -19.9% |
| Basic EPS | -0.66 | -0.88 | -5.45 | -4.95 | +25.0% |
| Diluted EPS | -0.66 | -0.88 | -5.45 | -4.95 | +25.0% |
| EBIT | -$4.49M | -$3.73M | -$1.58M | -$1.23M | -20.6% |
| EBITDA | -$4.49M | -$3.73M | -$1.58M | -$1.23M | -20.6% |
| Basic shares | 6.79M | 4.38M | 347.00K | 345.96K | +54.9% |
| Diluted shares | 6.79M | 4.38M | 347.00K | 345.96K | +54.9% |
| Line item | 2026-06-30 | 2026-03-31 | YoY |
|---|---|---|---|
| Cash & equivalents | $61.96M | $6.36M | +873.8% |
| Cash & short-term investments | $61.96M | $6.36M | +873.8% |
| Total current assets | $63.39M | $8.50M | +645.5% |
| Total assets | $63.39M | $8.50M | +645.5% |
| Total current liabilities | $16.97M | $16.09M | +5.5% |
| Total liabilities | $16.97M | $16.09M | +5.5% |
| Retained earnings | -$308.84M | -$304.33M | -1.5% |
| Shareholder equity | $46.42M | -$7.58M | +712.1% |
| Working capital | $46.42M | -$7.58M | +712.1% |
| Net tangible assets | $46.42M | -$7.58M | +712.1% |
| Shares issued | 3.44M | 461.18K | +645.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|
| Net income | -$4.50M | -$3.75M | -$1.89M | -$1.71M | -19.9% |
| Stock-based compensation | $95.00K | $46.00K | $16.00K | $20.00K | +106.5% |
| Change in working capital | -$452.00K | -$1.70M | $10.00K | $2.63M | +73.3% |
| Operating cash flow | -$4.79M | -$5.45M | -$1.75M | $1.20M | +12.2% |
| Financing cash flow | $60.39M | $7.03M | $1.88M | -$865.00K | +758.9% |
| Free cash flow | -$4.79M | -$5.45M | -$1.75M | $1.20M | +12.2% |
| End cash position | $61.97M | $6.37M | $577.00K | $455.00K | +872.9% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | — | -0.66 | — |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.61 | 2 | $0 | — |
| Next quarter | -0.70 | 2 | $0 | — |
| Current year | -2.10 | 3 | $0 | — |
| Next year | -2.72 | 3 | $0 | 0.0% |
Analyst targets & ownership
Mean target$38.25
High target$43.00
Low target$32.00
Implied upside152.81%
Analyst count4
ConsensusNONE
Strong buy / Buy0 / 4
Hold0
Sell / Strong sell0 / 0
Held by insiders19.06%
Held by institutions73.76%
Institutions holding25
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
15.40
-1.73% from price
SMA 20
16.18
-6.51% from price
SMA 50
16.75
-9.67% from price
SMA 100
—
—
SMA 200
—
—
EMA 12
15.67
-3.45% from price
EMA 26
16.02
-5.56% from price
EMA 50
15.62
-3.12% from price
RSI (14)
44.0
Neutral
MACD (12,26,9)
-0.35
Hist -0.11
ATR (14)
1.40
9.23% of price
Realised vol 30D
93.8%
Annualised
Bollinger upper
18.11
20, 2σ
Bollinger lower
14.26
20, 2σ
50 / 200 cross
—
—
Trend bias
—
—
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
2.09
More volatile than market
Correlation to SPY
0.22
Largely independent
Realised vol 30D
93.8%
Annualised
Market vol 1Y
12.2%
SPY, annualised
Max drawdown 1Y
-32.4%
Peak to trough
Max drawdown 5Y
-32.4%
Peak to trough
ATR 14
1.40
9.23% of price
Beta (reported)
-171,332.88
5Y monthly, from filing
Short interest
Shares short
45.63K
Prior 24.45K
Change vs prior
+86.6%
Shorts adding
% of float
1.25%
Normal
% of shares out
1.13%
Against total outstanding
Days to cover
1.0
Liquid
Float
931.13K
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 18, 26 | Leerink Partners | INITIATED | — | Outperform |
| Aug 24, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Aug 20, 26 | LUCID CAPITAL MARKETS | INITIATED | — | Buy |
| Jul 22, 26 | LifeSci Capital | INITIATED | — | Outperform |
| Jul 20, 26 | Guggenheim | INITIATED | — | Buy |
| Jul 11, 23 | Oppenheimer | MAINTAINED | Outperform | Outperform |
| Apr 6, 23 | Oppenheimer | MAINTAINED | — | Outperform |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay dateDec 20, 2017
Last split—
Split date—
SEC filings
Offering Registrations
S-1 · 2026-09-11
Periodic Financial Reports
10-Q · 2026-08-11
Offering Registrations
S-1/A · 2026-06-04
Trading Registrations
8-A12B · 2026-06-01
Proxy Statements
DEF 14C · 2026-05-08
Offering Registrations
S-1 · 2026-05-07
Periodic Financial Reports
10-Q · 2026-05-05
Corporate Changes & Voting Matters
8-K · 2026-05-01
Headlines
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.